title: Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis.
abstract: Osteopetrosis is a congenital metabolic bone disease characterized by skeletal sclerosis resulting from defective osteoclast-mediated bone resorption. The disease may, inter alia, be caused by the administration of bisphosphonates (e.g. pamidronate) particularly in young humans. The issue of the effect of pamindronate-induced osteopetrosis on the function of blood circulation and autonomic nervous system remains open. In order to clarify this problem, the present study concentrated on the effect of catecholamines on blood pressure in the marrow cavity in rats with pamindronate-induced osteopetrosis. The experiments consisted in pamidronate administration to young male Wistar rats at doses of 3 mg/kg sc, for 3 or 6 weeks. Norepinephrine, epinephrine, isoprenaline as well as adrenoceptor antagonists (phentolamine and propranolol) were administered to the controls and the rats with pamindronate-induced osteopetrosis. The examinations demonstrated that rats with pamidronate-induced osteopetrosis displayed increased blood pressure in the marrow cavity. In addition, a disorder in the effect of catecholamines on blood pressure in the marrow cavity of osteopetrotic bone was observed.
authors.affiliation: Department of Pharmacology, Medical University of Silesia, Jagiellońska 4, PL 41-200 Sosnowiec, Poland. farmak@slam.katowice.pl
authors.forename: Ilona
authors.initials: I
authors.lastname: Kaczmarczyk-Sedlak
authors.forename: Waldemar
authors.initials: W
authors.lastname: Janiec
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D050071:Bone Density Conservation Agents; D001853:Bone Marrow / Q000098:blood supply* / Q000187:drug effects; D002339:Carotid Arteries / Q000187:drug effects; D002395:Catecholamines / Q000494:pharmacology*; D004164:Diphosphonates; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D010022:Osteopetrosis / Q000139:chemically induced* / Q000503:physiopathology*; D000077268:Pamidronate; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D050071:Bone Density Conservation Agents; D002395:Catecholamines; D004164:Diphosphonates; D011433:Propranolol; D007545:Isoproterenol; D000077268:Pamidronate; D010646:Phentolamine